SOURCE: IO Circuit

November 18, 2011 07:30 ET

Positron, Corp. Looking to Expand the Supply of Medical Grade Strontium-82

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO CIRCUIT.

NEW YORK, NY--(Marketwire - Nov 18, 2011) - Positron Corp. (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, has announced its collaborative effort with the France based ARRONAX Cyclotron Facility to increase the supply of Strontium-82 (Sr-82).

In a Los Alamos National Laboratory article (, it is highlighted "Strontium-82 is used in Positron Emission Tomography (PET) to help diagnose heart disease. Hospitals nationwide diagnose about 400 patients every day using PET." And "The national demand for radioisotopes is extraordinary. Radioisotopes are vital to medical treatment and research, industry, agriculture, environmental science, and for defense applications."

Companies that manufacture PET machines are Siemens (NYSE: SI), Philips (NYSE: PHG) and General Electric (NYSE: GE).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO Circuit twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information